RLN3 Antibody

Code CSB-PA006898
Size US$100
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
RLN3
Alternative Names
RLN3 antibody; INSL7 antibody; RXN3 antibody; ZINS4 antibody; UNQ6188/PRO20213 antibody; Relaxin-3 antibody; Insulin-like peptide INSL7 antibody; Insulin-like peptide 7 antibody; Prorelaxin H3) [Cleaved into: Relaxin-3 B chain; Relaxin-3 A chain] antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Synthesized peptide derived from the Internal region of Human Relaxin 3.
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Form
Liquid
Tested Applications
IHC, ELISA
Recommended Dilution
Application Recommended Dilution
IHC 1:100-1:300
ELISA 1:40000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
May play a role in neuropeptide signaling processes. Ligand for LGR7, RXFP3 and RXFP4.
Gene References into Functions
  1. Serum level of relaxin-3 hormone is an important mediator in the pathophysiological process of normal puberty being significantly decreased in males with delayed puberty. PMID: 28786126
  2. Therefore, we conclude that stapling of the relaxin3 B chain does not compromise its ability to activate RXFP3 and is a promising method for developing stable peptide agonists and antagonists of RXFP3 to aid relaxin-3/RXFP3 research. PMID: 27498038
  3. the relaxin-3 B-chain C-terminus changes from the original folding-back conformation to an extended conformation during binding with RXFP3, to allow its B27Trp and B26Arg residues to interact with the Trp138 and Glu141 residues of RXFP3, respectively. PMID: 27193232
  4. In a population of acute HF patients, admission relaxin serum levels were associated with clinical and echocardiographic markers of pulmonary hypertension, RV dysfunction, and overload, suggesting a role for circulating relaxin as a biomarker in this setting. PMID: 27488261
  5. the negatively charged transmembrane aspartate residue controls activation of the relaxin-3 receptor RXFP3 PMID: 27353281
  6. Relaxin-3 is a high-efficacy agonist at RXFP4 with a comparable signal transduction profile to INSL5. PMID: 27888281
  7. Serum concentrations of relaxin showed a positive association to duration of gestation among women with miscarriage but no association to duration of gestation among women with spontaneous onset of labour. PMID: 26272327
  8. Review of research depicts the connection of relaxin-3 with phenomena such as feeding behavior, spatial memory, sleep/wake cycle or modulation of pituitary gland hormone secretion. PMID: 24988606
  9. we demonstrated distinct patterns of signalling for H3 and H2 relaxin and R3(BDelta23-27)R/I5 at the RXFP3 receptor PMID: 24641548
  10. Glu141 and Asp145 of the RXFP3 interact with the highly conserved arginine residues of relaxin-3. PMID: 24615237
  11. Mutant relaxin-3 shows a significant decrease in receptor-activation potency towards RXFP4. PMID: 24802387
  12. Relaxin-2 or relaxin-3 levels are not related to component traits in patients with diabetes. PMID: 23994775
  13. metabolic syndrome is associated with increased serum relaxin-3 levels in women PMID: 23018057
  14. [review] Relaxin-3 (RXF3P) is expressed within GABA neurons of the brainstem including an area known as the nucleus incertus; ascending relaxin-3 projections innervate a broad range of RXFP3-rich forebrain areas. PMID: 21693186
  15. H3 relaxin exerts antifibrotic actions via RXFP1 receptor PMID: 21229994
  16. Relaxin-3 and receptors in the human and rhesus brain and reproductive tissues. PMID: 19778557
  17. relaxin-3/INSL7 is a ligand for GPCR142 PMID: 14522967
  18. GPCR135 is the receptor for relaxin-3 PMID: 14522968
  19. RLN3 chimeric peptide is a potential tool to study in vivo function of GPCR135. PMID: 15465925
  20. Intracerebroventricular injections of human relaxin-3 (H3) to satiated rats significantly increased food intake. PMID: 15845619
  21. NMR spectroscopy and simulated annealing calculations were used to determine the three-dimensional structure of relaxin-3 and to identify key structural differences between the human relaxins. PMID: 15956686
  22. functional response to H3 relaxin and other relaxin/insulin peptides of GPCR135 expressed in CHO-K1 cells was measured in the cytosensor microphysiometer and analyzed using inhibitors of signal transduction proteins PMID: 15956730
  23. Results describe the solution structure of human relaxin-3. PMID: 16365033
  24. Results decribe the structural and functional aspects of the interaction between relaxin-3 and its receptor, RXFP3. PMID: 19152634

Show More

Hide All

Subcellular Location
Secreted.
Protein Families
Insulin family
Database Links

HGNC: 17135

OMIM: 606855

KEGG: hsa:117579

STRING: 9606.ENSP00000397415

UniGene: Hs.352155

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*